Focus: Takeda is a 49,000-person Japanese pharmaceutical giant with a diversified portfolio spanning small molecules and biologics across GI, rare diseases, neuroscience, and oncology. The company generates significant revenue from peak-stage products like TRINTELLIX (26% of revenue concentration) and maintains a global scale commensurate with Big Pharma.
Profile data last refreshed 15h ago · AI intelligence enriched 1mo ago
Hot — 1608 jobs added in 30d
Net +970 (1608 new, 638 removed). Aggressive expansion phase.
4 recent layoff filings (12 mo) — 500 affected
Source: state DOL filings via Big Local News
Takeda offers scale, therapeutic diversity, and global infrastructure, but structural headwinds—layoffs, patent cliffs, and lean pipeline depth—require confidence in company's acquisition integration and clinical readout trajectory.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Flagship revenue driver (26% of company total); stable peak revenue and 2032 LOE provides 6+ year revenue runway.
Help build intelligence for Takeda
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Takeda's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Second-largest revenue contributor; oncology franchise anchor with 2029 LOE creating near-term patent cliff risk.
Significant revenue base but approaching loss of exclusivity; pipeline includes Phase 3 binge eating disorder expansion attempt.
Oncology kinase inhibitor with extended LOE horizon (2033); niche indication but solid peak revenue.
Biologic integrin antagonist in GI franchise; no LOE date signals potential exclusivity extension and growth runway in IBD.
Established GI PPI with solid revenue base; 2032 LOE creates mid-term generic competition risk.
Specialized GI motility agent; earliest patent cliff (2028) and $62M revenue represents near-term erosion headwind.
Rare disease bradykinin B2 antagonist; no LOE date and niche market provide stable if modest revenue.
43 discontinued, 18 duplicate formulations not shown
+17 more products with revenue data
Takeda presents oncology data: what it means for Takeda stock - AD HOC NEWS
Takeda presents oncology data: what it means for Takeda stock AD HOC NEWS
Takeda Pharmaceutical Company Limited Announces New Data From VERDICT Showing Treating Adults With Intravenous ENTYVIO To Achieve Corticosteroid-Free Disease Clearance Prolongs Time To First Ulcerative Colitis-Related Complication - marketscreener.com
Takeda Pharmaceutical Company Limited Announces New Data From VERDICT Showing Treating Adults With Intravenous ENTYVIO To Achieve Corticosteroid-Free Disease Clearance Prolongs Time To First Ulcerative Colitis-Related Complication marketscreener.com
Takeda Pharmaceutical (TSE:4502) Launches ORZEYFUL, Is It Still 6% Undervalued? - Simply Wall Street
Takeda Pharmaceutical (TSE:4502) Launches ORZEYFUL, Is It Still 6% Undervalued? Simply Wall Street
Takeda Pharmaceutical Company Limited Stock 12‑Month Price Target Raised to $20.74, Implies 9% Upside - TradingView
Takeda Pharmaceutical Company Limited Stock 12‑Month Price Target Raised to $20.74, Implies 9% Upside TradingView
Takeda Pharmaceutical : to Hold Earnings Call for Fiscal Year 2026 2nd Quarter on October 29 - www.marketscreener.com
Takeda Pharmaceutical : to Hold Earnings Call for Fiscal Year 2026 2nd Quarter on October 29 www.marketscreener.com
Analysts raise target for Takeda Pharmaceutical stock to JPY 5,800 - AD HOC NEWS
Analysts raise target for Takeda Pharmaceutical stock to JPY 5,800 AD HOC NEWS
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Analysis of healthcare resource utilization before and after initiation of maribavir for cytomegalovirus treatment.
Bleeding rates, healthcare utilization, and costs among patients with hemophilia a without inhibitors treated with concomitant octocog alfa or extended half-life factor VIII while on emicizumab prophylaxis.
+5 more products
+2 more
+2 more
+2 more
+1 more
+2 more
Source: state DOL filings, aggregated via Big Local News
Repeated layoffs in core R&D hubs (Cambridge) and facility closures signal instability; job security concerns and potential organizational churn elevate departure risk within 18–24 months of hire.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo